Syncom Formulations (India) financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹126cr+7.4% on Q1 FY26
Net profit
₹24.8cr+57.7% on Q1 FY26
EBITDA margin
20.9%+7.4 pts on Q1 FY26
EPS
₹0.26+23.8% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue126117+7.4%
EBITDA26.215.8+65.8%
EBITDA margin20.9%13.5%+7.4 pts
Profit before tax32.320.3+58.9%
Net profit24.815.8+57.7%
EPS₹0.26₹0.21+23.8%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹126 crNet profit₹24.8 crNet margin19.8%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
1,911————
11211289.912763.1
1.51.54.672.583.2
1,801————
498489465263224
—+5.2%+76.6%+17.5%—
87.877.454.129.619.6
17.6%15.8%11.6%11.3%8.8%
81.170.948.924.915.1
85.576.449.425.320.1
17.2%15.6%10.6%9.6%9.0%
₹0.91₹0.81₹0.53₹0.27₹0.21
—+54.6%+95.3%+26.1%—
—58.123.4−6.010.5
—−11.7−10.0−8.1−20.6
46.446.413.5−14.1−10.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNCOMF₹20.33

Syncom Formulations (India) Limited

· Pharma & Health
₹ CrorePeersHESTERBIONGLFINEWINDLASJAGSNPHARMAMRUTANJANINDOCOSAIPARENTMcap ₹1,911 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————1,911.0
- Cash, Equiv & ST Investments63.1127.189.9111.7111.7
+ Total Debt83.272.54.61.51.5
Enterprise Value————1,800.8
Revenue224.3263.4465.0489.2497.8
Growth %, YoY—+17.5+76.6+5.2—
EBITDA19.629.654.177.487.8
Margin %8.7511.2611.6415.8317.64
EBIT15.124.948.970.981.1
Net Income20.125.349.476.485.5
Margin %8.959.6110.6315.6317.18
EPS, Adj (current shares)0.210.270.530.810.91
Growth %, YoY—+26.1+95.3+54.6—
Cash from Operations10.5-6.023.458.1—
Capital Expenditures-20.6-8.1-10.0-11.7—
Free Cash Flow-10.1-14.113.546.446.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Syncom Formulations financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Syncom Formulations (NSE: SYNCOMF) had a market capitalisation of ₹1,919 crore at the 29 October 2026 close (₹20.41 a share), a PE ratio of 22.4 on the last four quarters' profit and a price-to-book ratio of 4.62. In FY26 its consolidated net profit was ₹76.4 crore on revenue of ₹489 crore; in Q1 FY27 (April–June 2026) it was ₹24.8 crore, up 57.7% year on year. Its debt-to-equity ratio was 0.00 on 31 March 2026. Promoters held 50.57% of the shares on 30 September 2026.

Share price used
₹20.41 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Syncom Formulations at a glance · consolidated

Market cap
₹1,919 Crat ₹20.41 · 29 Oct close
PE ratio (last 4 quarters)
22.425.1 on FY26 profit
Price to book (PB)
4.62book value ₹4.41 a share
ROE (FY26)
20.2%+4.5 pts vs FY25ROCE 18.1%
Debt to equity
0.00net cash ₹111 Cr
Promoter holding
50.57%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.49%₹0.10 a share in 12 months
Net worth
₹415 Cr+21.3% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹46.4 Cr+244.4% vs FY25

Questions

What is the Syncom Formulations PE ratio today?

Syncom Formulations' PE ratio is 22.4 at the 29 October 2026 close (₹20.41 a share): a market capitalisation of ₹1,919 crore divided by consolidated net profit of ₹85.5 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹76.4 crore) it is 25.1.

What is the Syncom Formulations PB ratio (price to book value)?

Syncom Formulations' price-to-book (PB) ratio is 4.62 at the 29 October 2026 close: a market capitalisation of ₹1,919 crore divided by shareholders' equity (book value) of ₹415 crore on 31 March 2026. That is a book value of ₹4.41 per share against a share price of ₹20.41.

What is the Syncom Formulations book value per share?

Syncom Formulations' book value per share was ₹4.41 on 31 March 2026: shareholders' equity of ₹415 crore divided by the 94 crore shares in issue, up 21.3% from ₹3.64 a year earlier. The share price at the 29 October 2026 close was ₹20.41.

What is the Syncom Formulations market cap?

Syncom Formulations' market capitalisation was ₹1,919 crore at the 29 October 2026 close: 94 crore shares at ₹20.41 each.

What is the Syncom Formulations EPS?

Syncom Formulations' basic earnings per share (EPS) were ₹0.81 in FY26, against ₹0.57 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹0.94.

What is the Syncom Formulations dividend in 2026 and its record date?

In 2026, Syncom Formulations has declared one dividend: ₹0.10 with record date 23 September 2026.

Is Syncom Formulations debt free?

No. Syncom Formulations had borrowings of ₹1.5 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.00. Its cash and current investments were ₹113 crore, so it held net cash of ₹111 crore.

What is the Syncom Formulations debt to equity ratio?

Syncom Formulations' debt-to-equity ratio was 0.00 on 31 March 2026: borrowings of ₹1.5 crore against total equity of ₹415 crore. A year earlier, on 31 March 2025, it was 0.01.

What is the Syncom Formulations net worth?

Syncom Formulations' net worth — shareholders' equity in its consolidated balance sheet — was ₹415 crore on 31 March 2026, up 21.3% from ₹342 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,919 crore at the 29 October 2026 close.

What is the Syncom Formulations ROE and ROCE?

In FY26, Syncom Formulations' return on equity (ROE) was 20.2% and its return on capital employed (ROCE) was 18.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 15.7% and ROCE 15.0%.

What is the Syncom Formulations dividend yield?

Syncom Formulations' dividend yield is 0.49% at the 29 October 2026 close: dividends of ₹0.10 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹20.41. They were ₹0.10 on 23 September 2026.

What is the Syncom Formulations shareholding pattern?

On 30 September 2026, Syncom Formulations' shares were held by promoters 50.57%, foreign portfolio investors (FII/FPI) 2.22%, domestic institutions (DII) 0.00% (including mutual funds at 0.00%) and retail and other non-institutional investors 47.20%. Over the year, FII holding was up 2.12 percentage points from 0.10% and DII holding was unchanged.

What is the Syncom Formulations promoter holding?

Promoters held 50.57% of Syncom Formulations on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Syncom Formulations free cash flow?

In FY26, Syncom Formulations generated ₹58.1 crore of cash from operations and spent ₹11.7 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹46.4 crore. In FY25 it was ₹13.5 crore.

What are the Syncom Formulations latest quarterly results?

Syncom Formulations' latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit ₹24.8 crore, up 57.7% from ₹15.8 crore in Q1 FY26; revenue from operations ₹126 crore, up 7.4% year on year.

What is the Syncom Formulations revenue and profit in FY26?

In FY26 (April 2025–March 2026), Syncom Formulations' consolidated net profit was ₹76.4 crore, up 54.6% from ₹49.4 crore in FY25, on revenue from operations of ₹489 crore (up 5.2%). Over three years, from FY23, net profit was up 280.8%.

When are the Syncom Formulations next results?

Syncom Formulations has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does the Syncom Formulations PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Syncom Formulations' PE ratio is 25.1, the lowest of the four: Hester Biosciences 35.3, NGL Fine-Chem 33.5 and Windlas Biotech 29.3, a peer average of 32.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Syncom Formulations compare with its peers?

On FY26 consolidated figures, against Hester Biosciences, NGL Fine-Chem and Windlas Biotech: Syncom Formulations' operating margin of 14.5% is the second highest of the four (Hester Biosciences 20.4%, NGL Fine-Chem 10.6%, Windlas Biotech 8.2%; peer average 13.1%); its return on equity of 20.2% is the highest of the four (Hester Biosciences 16.5%, NGL Fine-Chem 15.7%, Windlas Biotech 12.2%; peer average 14.8%); its revenue growth over three years of 29.7% a year is the highest of the four (Hester Biosciences 7.7% a year, NGL Fine-Chem 21.7% a year, Windlas Biotech 20.8% a year; peer average 16.7% a year).

Syncom Formulations vs Hester Biosciences: how do they compare?

In FY26, Syncom Formulations earned net profit of ₹76.4 crore on revenue of ₹489 crore, against ₹55.6 crore on ₹333 crore for Hester Biosciences. Syncom Formulations' operating margin was 14.5% (Hester Biosciences 20.4%) and its return on equity 20.2% (Hester Biosciences 16.5%). At the 29 October 2026 close, Syncom Formulations' market capitalisation was ₹1,919 crore against ₹1,963 crore for Hester Biosciences, and its PE ratio on FY26 profit 25.1 against 35.3.

Where do these Syncom Formulations figures come from?

From Syncom Formulations' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.